<DOC>
	<DOCNO>NCT00025025</DOCNO>
	<brief_summary>RATIONALE : Screening test may help doctor detect cancer cell early plan effective treatment colorectal cancer . PURPOSE : Randomized screen trial compare effectiveness fecal occult blood test DNA-based test stool blood identify colorectal cancer .</brief_summary>
	<brief_title>Screening Tests Detecting Colorectal Cancer</brief_title>
	<detailed_description>Primary objective : 1 . To compare performance characteristic ( sensitivity , specificity , predictive value ) fecal MTAP widely-used fecal occult blood test ( Hemoccult ) identification screen-relevant colorectal neoplasia ( curablestage cancer advance adenoma high-grade dysplasia/carcinoma situ size ≥ 1.0 cm . ) 2 . To evaluate necessity formal pretest preparation MTAP compare specificity MTAP Hemoccult test subject group randomize pre-test preparation versus pre-test preparation . Secondary objective : 1 . To compare detection rate colorectal neoplasia fecal MTAP alone flexible sigmoidoscopy ( distal 60 cm colonoscopic examination serve surrogate ) combination sigmoidoscopy plus Hemoccult . 2 . To characterize compare pathological molecular feature screen-relevant colorectal neoplasm detect detected fecal MTAP . 3 . To explore sensitivity specificity MTAP apply plasma detection screen-relevant colorectal neoplasia . 4 . To maintain specimen bank comprise stool blood ( plasma ) subject tissue screen-relevant neoplasm . OUTLINE : This randomize , multicenter study . Participants stratify accord age ( 50-64 [ close accrual 6/5/03 ] vs 65-80 ) , gender ( male v female ) , participate center . Participants randomize one two screening arm . - Arm I : Participants eat red meat take nonsteroidal anti-inflammatory drug ( NSAIDs ) vitamin C multivitamins 3 day prior stool sample collection . Participants collect stool sample 3 different time perform fecal occult blood ( FOB ) test smear stool . After collection , participant ship whole stool FOB test smear participate center blind multitarget DNA-based assay panel ( MTAP ) test . - Arm II : Participants take vitamin C multivitamins 3 day stool sample collection . Participants collect stool sample FOB test smear sample test arm I . Within 2 month stool sample collection , participant blood draw additional MTAP test undergo colonoscopy . PROJECTED ACCRUAL : A total 4,000 participant ( 2,000 per arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Required Characteristics : 1 . ≥ 65 ≤ 80 year age . 2 . Females must postmenopausal ( absence menstrual period least one year ; patient regular hormone replacement therapy ; surgical intervention ) . Contraindications : 1 . FOBT screen ≤1 year prior randomization . 2 . Structural colorectal evaluation ( i.e . colonoscopy , colon xray , sigmoidoscopy ) ≤10 year prior randomization . 3 . Overt rectal bleeding ( hematochezia melena ) ≤1 month prior randomization . 4 . Prior colorectal resection reason . 5 . Inability stop therapeutic dos NSAIDs ( prophylactic dos aspirin ( ≤325 mg ) allow [ 121 ] Cox2 inhibitor ( i.e . Celebrex , Vioxx ) allow . ) 6 . Coagulopathy inablitity discontinue anticoagulant ( discontinuation must superviesed physician ) . 7 . Aerodigestive cancer ≤5 year prior randomization . 8 . Contraindications colonoscopy ( e.g. , serious cardiopulmonary disease ) . 9 . Highrisk condition colorectal cancer ( familial adenomatous polyposis , hereditary nonpolyposis colorectal cancer syndrome , hereditary cancer syndrome , prior colorectal cancer adenoma , inflammatory bowel disease , 2 firstdegree relative colorectal cancer ) . 10 . Chemotherapy ≤ 3 month prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>